Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-CLS-484 in Advanced Solid Tumors
NCT04777994Phase 1Recruiting
- Sponsor
- Calico Life Sciences
- Start
- Mar 2021
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of osunprotafib in solid tumor (6 arms), sponsored by Calico Life Sciences. Primary endpoints: Maximum Observed Plasma/Serum Concentration, Time To Cmax and 4 more. Started Mar 2021; status: recruiting.
02
Drugs
osunprotafib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04777994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777994.